Biotech Values

[DewDiligence]

…making it difficult for the new orals to be added to hospital protocol as a first-line prophylaxsis choice.

Agreed. The one exception may be where the alternative to one of the new oral anticoagulants is warfarin; however, warfarin isn’t widely used in the hospital setting, so this isn’t much of a business opportunity.

In the outpatient setting, on the other hand, the new oral anticoagulants will almost certainly become big-selling drugs, IMO.